BioSpace News Archive

The n-Lorem Foundation announced it has received a pledge of $500,000 from Paul and Andrea Compton in support of the n-Lorem Foundation’s efforts to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases.

LifeMax Laboratories, Inc. announced that the Food and Drug Administration granted fast track designation to LM-030, an investigational therapy licensed from Novartis and currently in a Phase 2/3 pivotal clinical trial for the treatment of Netherton Syndrome.

Invacare Corporation will participate in the 19th Annual Needham Healthcare Conference where the company’s management will provide a business update and share preliminary financial results for the first quarter ended March 31, 2020.

Cytokinetics, Incorporated provided an update regarding the company’s clinical trials and business operations related to its response to the COVID-19 pandemic alongside its commitment to prioritize the safety, health and wellbeing of patients, their caregivers, healthcare providers, partners and employees.

OpGen, Inc. announced that total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that Walter Klemp, Chairman and Chief Executive Officer, will host a web-based conference call on April 16th at 4:30pm ET

Intact Vascular’s Tack Endovascular System is a First-of-its-Kind Vascular Implant for Optimized Balloon Angioplasty Outcomes in Challenging CLI Patient Population

Phase 1 clinical study in patients with refractory NSCLC expected to begin in Second Quarter 2020

Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.

Seattle’s AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia.